<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>platinum chemotherapy response &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/platinum-chemotherapy-response/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 30 Sep 2025 18:28:30 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>platinum chemotherapy response &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Organoid Models Mirror Ovarian Cancer Platinum Response</title>
		<link>https://bioengineer.org/organoid-models-mirror-ovarian-cancer-platinum-response/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 30 Sep 2025 18:28:19 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[drug screening platforms]]></category>
		<category><![CDATA[ovarian cancer organoid models]]></category>
		<category><![CDATA[patient-derived xenograft tumors]]></category>
		<category><![CDATA[personalized cancer therapy]]></category>
		<category><![CDATA[platinum chemotherapy response]]></category>
		<guid isPermaLink="false">https://bioengineer.org/organoid-models-mirror-ovarian-cancer-platinum-response/</guid>

					<description><![CDATA[In the relentless battle against ovarian cancer—the deadliest among gynecological malignancies—a novel avenue of research is providing renewed hope and a significant stride towards personalized therapy. A recent study published in BMC Cancer introduces groundbreaking insights into the use of organoid models derived from both primary tumors and patient-derived xenograft (PDX) tumors, revealing their promising [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">273872</post-id>	</item>
	</channel>
</rss>
